Why Madrigal Pharmaceuticals, Inc.’s (MDGL) Stock Is Up 5.26%
As of Tuesday, August 04, Madrigal Pharmaceuticals, Inc.’s MDGL share price has surged by 5.26%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Stock Evaluator: Madrigal Pharmaceuticals, Inc. (MDGL)
Madrigal Pharmaceuticals, Inc. MDGL
$533.76
-9.93
-1.83%
August 28, 2026 4:00:00 PM
EST
Volume: 268,663
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Commentary & Analysis
Why Madrigal Pharmaceuticals, Inc.’s (MDGL) Stock Is Down 6.13%
As of Friday, July 31, Madrigal Pharmaceuticals, Inc.’s MDGL share price has dipped by 6.13%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Madrigal Pharmaceuticals, Inc.’s (MDGL) Stock Is Down 13.75%
As of Thursday, July 30, Madrigal Pharmaceuticals, Inc.’s MDGL share price has dipped by 13.75%, which has investors questioning if this is right time to buy.Michael Rose
Why Madrigal Pharmaceuticals, Inc.’s (MDGL) Stock Is Down 11.83%
As of Thursday, July 30, Madrigal Pharmaceuticals, Inc.’s MDGL share price has dipped by 11.83%, which has investors questioning if this is right time to buy.Jenna Brashear
What You Need to Know About Madrigal Pharmaceuticals, Inc.'s Q3 Earnings
Madrigal Pharmaceuticals, Inc.'s fiscal Q3 earnings report was released on Thursday, July 30. Let's dive in to see if (MDGL) missed or beat analyst's expectations.Michael Rose
Financial Summary
| Share Statistics | MDGL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $12,332.1 | $284.3 | 80% |
|
| Shares Out (Mil) | 23.1 | 54.1 | 32% |
|
| Institutional Ownership | 93.2% | 93.2% | 62% |
|
| Float (Mil) | 13.7 | 41.5 | 23% |
|
| Beta | -1.06 | 0.94 | 1% |
|
| Avg Daily Volume (000s) | 250 | 472 | 49% |
|
| Price Change (52-week) |
25.6% | 58.8% | 68% |
|
| Growth | MDGL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (7.4%) | (10.0%) | 31% |
|
| EPS (5yr) | 0.4% | 16.0% | 32 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 56.4% | (15.6%) | 94% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($1.088) | ($6.493) | $9.625 | |
| Month Ago EPS | ($1.033) | ($6.523) | $12.380 | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($1.033) | ($6.523) | $12.380 | |
| Year/Year Chg | (56.7%) | (49.5%) | (298.9%) | |
| Financials | MDGL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,284 | $37 | 54% |
|
| Net Income (TTM) (Mil) | ($325) | ($43) | 4% |
|
| EPS (TTM) | ($14.216) | ($1.500) | 3% |
|
| Operating Cash Flow (TTM) (Mil) | ($198) | ($32) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $102 | $2 | 77% |
|
| Long-Term Debt (Q1) (Mil) | $347 | $4 | 55% |
|
| Enterprise Value (Q1) (Mil) | $10,306 | $186 | 74% |
|
| Valuation | MDGL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 23.53 | 2.83 | 96% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | MDGL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 91.5% | 66.9% | 94% |
|
| Net Margin | (25.3%) | (73.5%) | 15% |
|
| ROA | (28.8%) | (47.7%) | 17% |
|
| ROE | (53.3%) | (55.0%) | 15% |
|
| Liabilities to Assets | 57.9% | 29.6% | 51% |
|
| F-Score | 2 | 2 | 7% |
|
Madrigal Pharmaceuticals, Inc. did not pass any screens on 8/28/2026.
